Navigation Links
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Date:6/15/2009

SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- Hollis-Eden Pharmaceuticals, Inc. (Nasdaq: HEPH), a leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, today announced the board of directors has appointed James M. Frincke Ph.D. as President and CEO of Hollis-Eden Pharmaceuticals, Inc. Dr. Frincke was also elected to the company's board of directors.

Dr. Frincke joined Hollis-Eden as Vice President, Research and Development in 1997, was promoted to Executive Vice President in 1999, and to Chief Scientific Officer in 2001. Dr. Frincke joined Hollis-Eden from Prolinx, Inc., where he served as Vice President, Therapeutics Research and Development from 1995 to 1997. During his 28 years in the biotechnology industry, Dr. Frincke has managed major development programs including drugs, biologicals, and cellular and gene therapy products aimed at the treatment of cancer, infectious diseases and organ transplantation. Since joining the biotechnology industry, Dr. Frincke has held vice president, research and development positions in top tier biotechnology companies including Hybritech/Eli Lilly and SyStemix Inc. (acquired by Novartis). In various capacities, he has been responsible for all aspects of pharmaceutical development including early stage research programs, product evaluation, pharmacology, manufacturing, and the management of regulatory and clinical matters for lead product opportunities. Dr. Frincke has authored or co-authored more than 100 scientific articles, abstracts and regulatory filings. Dr. Frincke received his B.S. in Chemistry and his Ph.D. in Chemistry from the University of California, Davis. Dr. Frincke completed his postdoctoral work at the University of California, San Diego. Dr. Frincke has been with Hollis-Eden for more than 11 years.


'/>"/>
SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
2. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
3. Jubilant to Work With Endo Pharmaceuticals on Drug Development
4. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
5. ADVENTRX Pharmaceuticals Announces Financing
6. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
7. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Inc. (NYSE: ALR ) (the "Company") announced today that, ... Quarterly Report on Form 10-Q for the three months ended ... notice from the New York Stock Exchange (the "NYSE") that ... listing requirements under the timely filing criteria established in Section ... The reason for the delay relates to Company,s need to ...
(Date:5/26/2015)...   PDI , a leader in infection ... Healthcare in Dearborn, Mich. ... Delivering the Difference , a ... building collaborative relationships between infection prevention (IP) and ... Oakwood Healthcare,s infection preventionist, Priscila ...
(Date:5/26/2015)... , 26. mája 2015 Kevin ... svojej rodiny prezidentom Barackovi Obamovi a Billovi Clintonovi ... so stratou Dr. Rongxiang Xu , otca ... Dr. Xu bol pionier, inovátor, ... jeho odhodlanie v oblasti vedy a príkladné vedenie ...
(Date:5/26/2015)... TORONTO , May 26, 2015 /PRNewswire/ - Fluorinov ... appointment of Luke M. Beshar to its ... adding financial and pharmaceutical industry expertise as Fluorinov accelerates ... of the Fluorinov team, it is a pleasure to ... had a significant impact on the strategy, financial strength ...
Breaking Biology Technology:PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3Dr. Rongxiang Xu, O legende 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3
... Milwaukee, Wis. - The Wisconsin Department of ... a $50,000 grant to the University of Wisconsin-Milwaukee ... from Wisconsin agricultural and forestry products. , ,The ... mechanical engineering at UWM, is designed to strengthen the ...
... - The candidates for Wisconsin governor are playing a game of ... Mark Green 's turn to up the ante after Gov. ... minimum markup law for ethanol. , ,Green, however, did not take ... markup, even though he once voted for legislation to repeal the ...
... - Merge eMed , a Merge ... announced the release of eFilm Spanish , a ... . , ,Released in October 2005, Workstation is a ... and CD burning of digital medical images. This functionality ...
Cached Biology Technology:UWM receives state funding for plastics research 2Green doesnt up the ante on markup law 2
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... scientists have begun to harness DNA,s powerful molecular machinery ... natural ability of pairs of DNA molecules to assemble ... the California Institute of Technology,* could provide a means ... and drug delivery systems, from the bottom up. ...
... . Sperm have only one aim: to find ... emitting attractants. Calcium ions determine the beating pattern of the sperm ... the Max Planck Institute for the Physics of Complex Systems in ... centre in Bonn, an institute of the Max Planck Society, have ...
... British Columbia is arguably the most important fossil deposit ... Cambrian "Explosion," the rapid flowering of complex life from ... comprised of shells, teeth and bones, the Burgess Shale ... delicate structuresof animals belonging to Earth,s earliest complex ecosystems ...
Cached Biology News:The shape of things to come: NIST probes the promise of nanomanufacturing using DNA origami 2Sperm can count 2Mechanism for Burgess Shale-type preservation 2
PAb to Hu-IFN-Alpha/Beta R2 [(IFNAR2) CD118], Rabbit Serum, neutralizing Binds to but does not neutralize human interferon alpha/beta receptor...
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
Biology Products: